Targeted Drug Delivery

animated video

EDV mediated drug delivery

EnGeneIC has invented methods by which a range of different chemotherapeutic drugs (cytotoxic as well as molecularly targeted) with differing structure, charge, hydrophobicity, and solubility, such as doxorubicin, paclitaxol, irinotecan, 5-fluorouracil, cisplatin, carboplatin, gemcitabine, vinblastine, and monastrol can be readily packaged within the EDVs. EDVs can then be targeted to a specific cancer cell by attachment of a bispecific antibody. One end of the bispecific antibody attaches to the EDV and the other end is available for binding to a surface receptor expressed by the cancer cell (See schematic above). Once delivered inside the cell via endocytosis the EDVs are broken down in the late endosomes and the chemotherapeutic drugs released into the cytoplasm, where they are taken up by the nucleus. The drugs have been shown to remain bioactive and to be cytotoxic to the targeted cells.

In-vivo therapeutic efficacy of bispecific antibody-targeted, drug-packaged EDVs has been evaluated in many human tumour xenograft experiments in mice.

These results are described in the three published papers. Essentially, all EDV-based therapeutics tested in different human tumour xenografts gave rise to a dramatic anti-tumour effects compared to various control treatments.

Targeted Drug Delivery
Gene Silencing
Canine Cancers
Principal Characteristics